Articles
30.08.2021
Blockbuster drugs of the next decade

Until June 30th, 2021, the FDA in the US and European Medicine Agency in Europe have launched 32 and...

Read more
Articles
26.08.2021
NICE remodel plans for January 2022

NICE’s remodel plans focus on delivering faster and fairer access to treatments by optimising appr...

Read more
Articles
23.08.2021
Indirect treatment comparisons guide

ITC can provide an estimate of the relative treatment effect of two products that have not been comp...

Read more
Articles
20.08.2021
NICE and AHSN collaboration

The agreement sets out to leverage the strengths of both organisations in embedding evidence-based h...

Read more
Articles
11.08.2021
Pharmaceutical tendering basics

In this article we break down the 3 core principles of the tendering process in a comprehensive summ...

Read more
Articles
06.08.2021
Healthcare performance comparison summary

The Common Wealth Fund has recently released a healthcare performance comparison report between 11 c...

Read more
Articles
05.08.2021
DTx Trends in EU5

The unprecedented growth of the Digital Therapeutic Market (DTx) has been one of the key highlights ...

Read more
Articles
04.08.2021
ICER puts spotlight on health insurers

ICER recently outlined its plans to annually assess Barriers to Fair Access within prescription drug...

Read more
News
04.08.2021
PMA Insights: Week 31 2021

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Articles
26.07.2021
New Innovative Medicines Fund

NHS England, the UK’s publicly funded healthcare system, will be introducing a £340m fund dedicat...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.